Literature DB >> 29029232

Immune checkpoint inhibitor-induced myo-fasciitis.

Dimitrios Daoussis1, Pantelis Kraniotis2, Stamatis-Nick Liossis1, Aikaterini Solomou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29029232     DOI： 10.1093/rheumatology/kex369

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  6 in total

Review 1.  Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.

Authors:  Karmela Kim Chan; Cynthia Magro; Alexander Shoushtari; Charles Rudin; Veronica Rotemberg; Anthony Rossi; Cecilia Lezcano; John Carrino; David Fernandez; Michael A Postow; Arlyn Apollo; Mario E Lacouture; Anne R Bass
Journal:  Oncologist       Date:  2019-10-15

2.  Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab.

Authors:  Matthew Js Parker; Mark E Roberts; Paul C Lorigan; Daniel G du Plessis; Hector Chinoy
Journal:  BMJ Case Rep       Date:  2018-02-08

Review 3.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

4.  Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors:  Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

5.  Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Authors:  Jan Leipe; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

6.  [Myofasciitis under nivolumab treatment].

Authors:  M Krusche; U Schneider; C Geisler; S Keller; W Stenzel; S Ohrndorf
Journal:  Z Rheumatol       Date:  2021-04-22       Impact factor: 1.372
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.